A number of potential chemoprevention agents are now in clinical trials to evaluate their efficacy. A larger number of compounds await clinical investigation. The design of phase I and phase II trials for cancer chemoprevention agents requires a different approach than for cytotoxic agents. The unique nature of the target populations, the scope of side effect evaluation, and the potential durat...

To integrate cancer chemoprevention information on a genomics basis, we have built a Web site named GenoCache (Genomics and Cancer Chemoprevention) that would provide users with a molecular biological view of cancer chemoprevention. The site is organized in four viewpoints: substances, genes or gene products with their genetic variations, cells or tissues with various cancer development states,...

Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face significant scientific, regulatory, and economic barriers, however, which have limited investment in their research and development (R&D). These barriers include above-average clinical trial scales, lengthy time frames between discovery ...

This work briefly reviews cancer chemoprevention. is a very challenging field, as products with high level of toxicity such chemotherapeutic agents may be proposed and accepted only under life-threatening conditions. Cancer chemoprevention otherwise limited to completely safe substances, preferably having neither toxic nor side effects, administered in relatively low amounts. Phases clinical tr...